パーキンソン病(PD)治療薬の世界市場2017-2021:ドーパミン作動薬 、MAO阻害剤、AChE阻害剤、グルタミン酸阻害剤、その他

【英語タイトル】Global Parkinson's Disease (PD) Drugs Market 2017-2021

Technavioが出版した調査資料(IRTNTR14672)・商品コード:IRTNTR14672
・発行会社(調査会社):Technavio
・発行日:2017年8月18日
・ページ数:85
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
TechNavioが出版した当調査レポートでは、パーキンソン病(PD)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、パーキンソン病(PD)治療薬の世界市場規模及び予測、薬剤種類別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社はパーキンソン病(PD)治療薬の世界市場が2017-2021年期間中に年平均3.81%成長すると予測しています。当レポート上に記載されている主な企業は• Boehringer Ingelheim• GlaxoSmithKline• Novartis• Teva Pharmaceutical Industries等です。
【レポートの概要】

About Parkinson’s Disease (PD) Drugs
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra. This lowers the concentration of dopamine in the striatum by 80%. This decrease in dopamine levels leads to symptoms associated with PD such as tremors, bradykinesia, and muscular rigidity. It is usually diagnosed after the age of 50 years; however, cases of earlier incidence have also been reported.

Technavio’s analysts forecast the global parkinson’s disease (PD) drugs market to grow at a CAGR of 3.81% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global parkinson’s disease (PD) drugs market for 2017-2021. To calculate the market size, the report considers sales/revenues and market share of the PD drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Parkinson’s Disease (PD) Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Boehringer Ingelheim
• GlaxoSmithKline
• Novartis
• Teva Pharmaceutical Industries

[Other prominent vendors]
• AbbVie
• Abital Pharma
• Addex Therapeutics
• Biogen
• Eisai
• Eli Lilly
• F. Hoffmann-La Roche
• H. Lundbeck
• Impax Laboratories
• Kyowa Hakko Kirin
• Otsuka Pharmaceutical
• Pfizer
• Prana Biotechnology
• Reviva Pharmaceuticals
• SK Biopharmaceuticals
• Takeda Pharmaceutical
• UCB

[Market driver]
• Rise in geriatric population
• For a full, detailed list, view our report

[Market challenge]
• Entry of generics
• For a full, detailed list, view our report

[Market trend]
• Emergence of biomarkers
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 06: Pipeline landscape

PART 07: Market segmentation by drug class
• Dopamine agonist
• MAO inhibitors
• AChE inhibitors
• Glutamate inhibitors
• Others

PART 08: Market segmentation based on geography
• PD drugs market in Americas
• PD drugs market in EMEA
• PD drugs market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges
• Market drivers
• Market challenges

PART 11: Market trends
• Emergence of biomarkers
• Gene therapy to reverse the progression of PD
• Advancing biomedical science
• Focus on regenerative therapies for mental disorders
• High growth potential of mAbs

PART 12: Vendor landscape
• Competitive scenario
• Key news

PART 13: Key vendor analysis
• Boehringer Ingelheim
• GlaxoSmithKline
• Novartis
• Teva Pharmaceutical Industries
• Other prominent vendors

PART 14: Appendix
• List of abbreviations

[List of Exhibits] Exhibit 01: Global PD drugs market: A snapshot
Exhibit 02: Global PD drugs market 2016-2021 ($ millions)
Exhibit 03: Opportunity analysis of global PD drugs market
Exhibit 04: Five forces analysis
Exhibit 05: Pipeline landscape based on number of molecules, 2016
Exhibit 06: Key clinical trials
Exhibit 07: Segmentation of global PD drugs market by drug class 2016
Exhibit 08: Global PD drugs market share by drug class 2016
Exhibit 09: Global PD dopamine agonist drugs market 2016-2021 ($ millions)
Exhibit 10: Global PD MAO inhibitors drugs market 2016-2021 ($ millions)
Exhibit 11: Global PD AchE inhibitors drugs market 2016-2021 ($ millions)
Exhibit 12: Global PD glutamate inhibitors drugs market 2016-2021 ($ millions)
Exhibit 13: Segmentation of global PD drugs market share by geography 2016 and 2021 (%)
Exhibit 14: Global PD drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 15: Global PD drugs market share by geography 2016-2021 (%)
Exhibit 16: PD drugs market scenario in different regions
Exhibit 17: Market scenario in Americas
Exhibit 18: PD drugs market in Americas 2016-2021 ($ millions)
Exhibit 19: Market scenario in EMEA
Exhibit 20: PD drugs market in EMEA 2016-2021 ($ millions)
Exhibit 21: Market scenario in APAC
Exhibit 22: PD drugs market in APAC 2016-2021 ($ millions)
Exhibit 23: Geriatric population analysis and estimates in 2000 and 2030 (millions)
Exhibit 24: Revenue erosion of PD drugs after loss of exclusivity
Exhibit 25: Planned clinical trials of iPS cell-based therapies
Exhibit 26: Competitive structure analysis of global PD drugs market 2016
Exhibit 27: Boehringer Ingelheim: Key highlights
Exhibit 28: Boehringer Ingelheim: Strength assessment
Exhibit 29: Boehringer Ingelheim: Strategy assessment
Exhibit 30: Boehringer Ingelheim: Opportunity assessment
Exhibit 31: GlaxoSmithKline: Key highlights
Exhibit 32: GlaxoSmithKline: Strength assessment
Exhibit 33: GlaxoSmithKline: Strategy assessment
Exhibit 34: GlaxoSmithKline: Opportunity assessment
Exhibit 35: Novartis: Key highlights
Exhibit 36: Novartis: Strength assessment
Exhibit 37: Novartis: Strategy assessment
Exhibit 38: Novartis: Opportunity assessment
Exhibit 39: Teva Pharmaceutical Industries: Key highlights
Exhibit 40: Teva Pharmaceutical Industries: Strength assessment
Exhibit 41: Teva Pharmaceutical Industries: Strategy assessment
Exhibit 42: Teva Pharmaceutical Industries: Opportunity assessment



【掲載企業】

Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva Pharmaceutical Industries, AbbVie, Abital Pharma, Addex Therapeutics, Biogen, Eisai, Eli Lilly, F. Hoffmann-La Roche, H. Lundbeck, Impax Laboratories, Kyowa Hakko Kirin, Otsuka Pharmaceutical, Pfizer, Prana Biotechnology, Reviva Pharmaceuticals, SK Biopharmaceuticals, Takeda Pharmaceutical, and UCB.


【レポートのキーワード】

パーキンソン病(PD)治療薬、ドーパミン作動薬 、MAO阻害剤、AChE阻害剤、グルタミン酸阻害剤、その他

★調査レポート[パーキンソン病(PD)治療薬の世界市場2017-2021:ドーパミン作動薬 、MAO阻害剤、AChE阻害剤、グルタミン酸阻害剤、その他] (コード:IRTNTR14672)販売に関する免責事項を必ずご確認ください。
★調査レポート[パーキンソン病(PD)治療薬の世界市場2017-2021:ドーパミン作動薬 、MAO阻害剤、AChE阻害剤、グルタミン酸阻害剤、その他]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆